Digital

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Source: Marina Temkin · Published Sep 23, 2026, 9:31 PM

The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.

In Digital, Marina Temkin puts this story at the center of the day: The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s. FlexChar is surfacing it because it is driving searches and conversation right now.

FlexChar editorial brief. The full report belongs to the original publisher; here you get the headline, context and the link.

Read the original story

Blog

Basic digital privacy: 9 changes that actually matter Free digital tools that are still worth it in 2026 How to plan your week without another productivity app Slow Windows: how to fix it in 2026 without a panic format

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

You may also like

U.S. Intervention in the UN Security Council Meeting on "Artificial Intelligence and International Security"

Artificial Intelligence Will Not Make Us Extinct

If Amazon doesn’t know how to eliminate carbon emissions, then who does?

US diplomats told to use term ‘super intelligence’ not ‘artificial intelligence’ after Trump's call